VITR Vitrolife AB (publ)
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware products, such as dishes, pipettes, tubes, and VitroTemp. The company was incorporated in 1989 and is based in Gothenburg, Sweden.…
Industry Peers
Medical DevicesKey Statistics
About Vitrolife (STO: VITR)
›
Vitrolife (STO: VITR) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 1,088 employees.
The shares were at 117.40 SEK on 19 November 2026, down 18.0% over 52 weeks. Its 52-week range is 84.00 SEK to 152.50 SEK: the price is 23.0% below the high and 39.8% above the low.
Its market capitalisation is 15.58B SEK. It pays a dividend yielding 0.93% (it pays out 34% of its earnings), against a median of 2.36% among the dividend payers in that peer group.
Vitrolife reports return on equity of -63.5%, an operating margin of 19.4% and revenue up 5.9% year over year.
Its debt exceeds its cash by 865.00M SEK, a debt-to-equity ratio of 0.20. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 5 analysts cover the stock; their mean price target of 133.00 SEK is 13.3% above the current price. The next earnings report is expected on 28 January 2027.